Introduction
1 in every 8 women are expected to develop Breast Cancer in their lifetime, and it functions as the second leading cause of death for women in the United States. Yet, between thirty and fifty percent of all cancers are preventable, and clinical interventions that meaningfully reduce the risk of developing cancer exist, and hereditary cancer risks are well understood. However, healthcare infrastructures that vary by region struggle to operationalize prevention-based solutions, particularly in the United States. In other words, the mortality of breast and ovarian cancer is not always dependent on the strength of the cancer itself, but on the infrastructure surrounding detection, treatment, and access. Recent advances, such as CRISPR-based genomic analysis, can now characterize cancerous mutations with enough precision to flag elevated risks of cancer years before a single malignant cell appears. This capacity for early and individualized risk prediction is one of the most promising frontiers in preventative oncology. Yet, clinical and public health systems that are responsible for translating the scientific advances into patient outcomes suppress the potential that such technologies have in making progress in reducing cancer risk.
CRISPR
CRISPR-based saturation genome editing has significantly advanced the characterization of BRCA1 and BRCA2— tumor suppressor genes in which the accumulation of DNA damage elevates the risk of cancer— variants. This breakthrough has allowed researchers to distinguish pathogenic mutations from benign mutations, increasing the accuracy of individual risk stratification. These technologies, pioneered by Dr. Jennifer Doudna’s lab, are also being leveraged therapeutically to engineer more effective immune responses to cancerous sites. It has applications in enhancing CAR-T cells and tumor-infiltrating lymphocytes (TILs), which can target genes that suppress immune response to malignant cells. However, the limitations of these interventions are important to note. No approved therapy currently uses CRISPR to edit BRCA genes in healthy, high-risk individuals, even as a preventative measure.
Currently, the FDA requires strong clinical evidence before approval, prioritizing patients with severe or life-threatening conditions with limited alternatives. This standard, combined with liability concerns and insurance reimbursement constraints, puts somatic editing— individual gene editing—, and germline editing— a gene editing technique that will affect the individual’s descendants— at a farther distance. As of current technological advancement, CRISPR-based cancer treatment applications are used as a tool for prediction and treatment augmentation, rather than prevention in terms of hereditary risk. The gap between scientific capability and accessible clinical application is not a negligible detail, but a defining detail of this intervention being applied in clinical settings.
Systematically Rooted Prevention
The constraints on clinical applications of preventative technologies such as CRISPR-based interventions are not solely regulatory or mechanistic, but they are also deeply systemic. Beyond genomic editing, the question lies in whether existing prevention infrastructure can act on what current tools already make possible. Centralized systems, such as European healthcare models, particularly operate under single-payer frameworks. These models invest in preventative measures, which save future treatment costs. Population-level screening programs, proactive hereditary tracking, and standardized referral pathways for genetic counseling mean that high-risk individuals are identified systematically. In effect, the system assumes responsibility for finding the patients who hold elevated risks for cancer. Contrarily, historically, the United States healthcare system has a strong capacity to finance and deliver care for diseases that have already been established. This means investing more in late-stage treatment and acute care.
The underinvestment in prevention and early detection-based care could have reduced the demand for these services in the first place. Private insurers, reimbursement structures, and hospital revenue models are all organized around diagnoses, late-stage treatment, and procedures. A patient could formally qualify for a risk assessment under the United States Preventive Services Task Force (USPSTF) recommendations, but still face issues in truly getting tested because of primary care access barriers, insurer conflict, geographic constraints, authorization, and surveillance delays. In the US, eligibility and access are not nearly the same thing, and functioning under multi-payer systems where coverage is dependent on employment, private insurance, income, and even geographical access, longitudinal prevention pathways become structurally difficult to maintain. Unlike centralized systems in Europe, where the system finds the patient, in the US, the patient has to navigate through the system themselves. The result is that BRCA-positive patients who need structured and longitudinal care are far less likely to receive it consistently in systems like these.
Conclusion
Scientific advancements are not what fail these patients. Biological targets and causes are understood, clinical evidence exists, and tools such as CRISPR-based genomic analysis are being sharpened every calendar year. Centralized systems show us what could be, and that prevention financing isn’t contingent on advancement, but systemic access. Yet for a significant portion of the population, even in the global north, this remains inaccessible. Every woman who develops breast or ovarian cancer, having never been flagged as high-risk, never referred for genetic counseling or surveillance, is not a casualty that results from scientific failure. The gap between what these interventions can do and who they meaningfully reach widens because scientific advancement scales faster than the structural reforms that are required to make it accessible equitably.